Abstract:Glial fibrillary acidic protein (GFAP) is a well‐established biomarker of reactive astrogliosis in the central nervous system. In this review, we explore how the physicochemical characteristics of GFAP may influence its detection, which may underlie the differential diagnostic performance of GFAP in different biological fluids and can provide valuable insights into underlying biological processes. We summarise how knowledge of GFAP biology and proteoforms, including isoforms, post‐translational modifications, discharge mechanisms, breakdown products, higher‐order species and interacting partners, can be utilised to guide future biomarker test development and enhance disease pathology comprehension. Glial fibrillary acidic protein (GFAP) is a well‐established biomarker of reactive astrogliosis in the central nervous system because of its elevated levels following brain injury and various neurological disorders. The advent of ultra‐sensitive methods for measuring low‐abundant proteins has significantly enhanced our understanding of GFAP levels in the serum or plasma of patients with diverse neurological diseases. Clinical studies have demonstrated that GFAP holds promise both as a diagnostic and prognostic biomarker, including but not limited to individuals with Alzheimer's disease. GFAP exhibits diverse forms and structures, herein referred to as its proteoform complexity, encompassing conformational dynamics, isoforms and post‐translational modifications (PTMs). In this review, we explore how the proteoform complexity of GFAP influences its detection, which may affect the differential diagnostic performance of GFAP in different biological fluids and can provide valuable insights into underlying biological processes. Additionally, proteoforms are often disease‐specific, and our review provides suggestions and highlights areas to focus on for the development of new assays for measuring GFAP, including isoforms, PTMs, discharge mechanisms, breakdown products, higher‐order species and interacting partners. By addressing the knowledge gaps highlighted in this review, we aim to support the clinical translation and interpretation of GFAP in both CSF and blood and the development of reliable, reproducible and specific prognostic and diagnostic tests. To enhance disease pathology comprehension and optimise GFAP as a biomarker, a thorough understanding of detected proteoforms in biofluids is essential.

14-3-3Γ Affects Dynamics and Integrity of Glial Filaments by Binding to Phosphorylated GFAP

Alterations in expression of GFAPmRNA and correlated protein after cerebral ischemia/reperfusion in rats

14-3-3? Is upregulated by in vitro ischemia and binds to protein kinase Raf in primary cultures of astrocytes

Reactive glial cells: increased stiffness correlates with increased intermediate filament expression.

GFAP-isoforms in the nervous system: Understanding the need for diversity

Direct interaction with 14-3-3γ promotes surface expression of Best1 channel in astrocyte

Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection

Synergistic effects of GFAP and Aβ42: Implications for white matter integrity and verbal memory across the cognitive spectrum

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

14-3-3 Proteins Interact with Neurofilament Protein-L and Regulate Dynamic Assembly of Neurofilaments

Glial Fibrillary Acidic Protein: Regulation by Hormones, Cytokines, and Growth Factors

INF2-mediated actin filament reorganization confers intrinsic resilience to neuronal ischemic injury

Phosphorylation of Tau by Glycogen Synthase Kinase 3β in Intact Mammalian Cells Influences the Stability of Microtubules

Astrocytic Damage in Glial Fibrillary Acidic Protein Astrocytopathy During Initial Attack.

A connexin43/YAP axis regulates astroglial-mesenchymal transition in hemoglobin induced astrocyte activation

ARG3.1/ARC expression in hippocampal dentate gyrus astrocytes: ultrastructural evidence and co-localization with glial fibrillary acidic protein.

The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases

Hormones and growth factors induce the synthesis of glial fibrillary acidic protein in rat brain astrocytes

Characterization of the Role of Full-Length CRMP3 and Its Calpain-Cleaved Product in Inhibiting Microtubule Polymerization and Neurite Outgrowth

Astrocytic proteins involved in regulation of the extracellular environment are increased in the Alzheimer's disease middle temporal gyrus

β-Amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3